ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Behçet’s Syndrome"

  • Abstract Number: 1566 • ACR Convergence 2022

    Outcome of Vascular Involvement of Behçet Syndrome Treated with Infliximab: A Retrospective Cohort Study

    gulen Hatemi1, Nur Beyza Tukek2, Sinem Nihal Esatoglu1, Yesim Ozguler3, Sitki Safa Taflan2, Melike Melikoglu1, Serdal Ugurlu4, Izzet Fresko1, Zekayi Kutlubay5, Sebahattin Yurdakul1, Hasan Yazici6 and Vedat Hamuryudan7, 1Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, New York, NY, 4Istanbul University-Cerrahpaşa, Istanbul, Turkey, 5Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, Turkey, 6Letter to Editor Rheumatology, Istanbul, Turkey, 7Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: Vascular involvement is an important cause of morbidity and mortality in patients with Behçet syndrome (BS). We aimed to survey the efficacy and safety…
  • Abstract Number: 0695 • ACR Convergence 2022

    Epidemiology of Behçet’s Disease in Northern Spain

    Carmen Alvarez Reguera1, guillermo Suárez-Amorin1, Rosalía Demetrio-Pablo1, Raúl fernández-ramón1, Alba Herrero-Morant2, Lara Sánchez-Bilbao1, David Martínez-López1, José Luis Martín-Varillas3, Santos Castañeda4, Miguel Ángel González-Gay5 and Ricardo Blanco6, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 3Hospital de Laredo, Laredo, Cantabria, Spain, 4Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 5Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 6Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: The prevalence of Behçet’s disease (BD) has a considerable geographical and temporal variability. Data regarding epidemiology in Spain are limited. Our study aimed to…
  • Abstract Number: 1567 • ACR Convergence 2022

    Refractory Macular Edema Due to Behçet’s Disease. Multicenter Comparative Study of Adalimumab and Certolizumab Pegol

    José Luis Martín-Varillas1, Lara Sánchez-Bilbao2, Vanesa Calvo Río3, Alf Adán4, Inés Hernanz Rodríguez4, Miguel Cordero Coma5, David Díaz Valle6, Patricia Fanlo7, Juan Ramón de Dios8, A. Garcia-Aparicio9, Sergio Rodriguez Montero10, Vega Jovani Casano11, Patricia Moya Alvarado12, eva Peña Sainz-Pardo13, José Luis Hernández2 and Ricardo Blanco14, 1Hospital de Laredo, Laredo, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Valdecilla Hospital, Santander, Spain, 4H. Clinic, Barcelona, Spain, 5Hospital de León, León, Spain, 6Hospital Clínico San Carlos, Madrid, Spain, 7Complejo Hospitalario de Navarra, Navarra, Spain, 8Hospital de Araba, Araba, Spain, 9Hospital Universitario de Toledo, Toledo, Spain, 10Virgen de Valme University Hospital, Sevilla, Spain, 11National Health system, Alicante, Spain, 12Hospital Parc Tauli, Barcelona, Spain, 13Hospital Universitario 12 de Octubre, Madrid, Spain, 14Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Cystoid Macular Edema (CME) is the leading cause of blindness in non-infectious uveitis. Behçet's disease (BD) is one of the diseases most frequently associated…
  • Abstract Number: 1041 • ACR Convergence 2022

    Tofacitinib in Refractory Uveitis – an Observational Study

    Nikhil Gupta1 and Deepankur Mahajan2, 1Centre for Arthritis and Rheumatological diseases in Delhi, New Delhi, India, 2Mahajan Eye Centre, New Delhi, India

    Background/Purpose: To evaluate the effect of generic tofacitinib in refractory uveitis patients.Methods: It was a prospective observational study of 23 patients of refractory anterior uveitis.…
  • Abstract Number: 1701 • ACR Convergence 2022

    High TNFAIP3-Transfected Cell Activity: An In Vitro Model for Phagocyte Study of Monogenic Behçet’s Disease Pathophysiology

    Patricia Pontes Aires1, André Cunha1, DANIELA GERENT PETRY PIOTTO1, Maria Teresa Terreri2 and Sandro Perazzio1, 1Universidade Federal de São Paulo, São Paulo, Brazil, 2Universidad Federal São Paulo, São Paulo, Brazil

    Background/Purpose: A20 haploinsufficiency (A20HA), an important monogenic etiology of Behçet's disease (BD), is caused by loss-of-function mutations in TNFAIP3. Although monocytes play an important role…
  • Abstract Number: 1237 • ACR Convergence 2022

    Assessment of Common Femoral Vein Intima-Media Thickness by Ultrasound in Behçet’s Disease: Comparative Study of Patients with or Without Vascular Involvement in a National Referral Center

    Diana Prieto-Peña1, Alfonso del Peral-Fanjul2, Belén Atienza-Mateo1, Veronica Pulito-Cueto1, Miguel Ángel González-Gay3 and Ricardo Blanco4, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain, Spain, 3Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Clinical vascular involvement is present in up to 40% of patients with Behçet’s disease (BD). Increased venous wall thickness assessed with ultrasound (US) has…
  • Abstract Number: 1837 • ACR Convergence 2022

    Eales Disease and Vogt-Koyanagi-Harada Syndrome: Not Everything Is Anterior Uveitis in Rheumatology

    Sonia Pastor Navarro1, Olga Compán Fernández1, Marta Ibáñez Martínez1, Belén Miguel Ibáñez1, Mireia Molina Pérez2, Ángel Beltrán Mazo2, Olga Martínez González1, Carlos Montilla Morales1, Ana Isabel Turrión Nieves1, Susana Gómez Castro3 and Cristina Hidalgo Calleja1, 1Hospital Universitario de Salamanca, Salamanca, Spain, 2Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, 3Hospital Universitario Salamanca, Salamanca, Spain

    Background/Purpose: Ocular inflammatory involvement for being closely related to systemic autoimmune diseases is monitored and treated in our rheumatology visits. The most frequently studied by…
  • Abstract Number: 1251 • ACR Convergence 2022

    Venous Halo Sign Detected with Superb Microvascular Imaging in Behçet Syndrome

    Yasemin Kayadibi1, Yesim Ozguler2, Melike Melikoglu3, Sinem Nihal Esatoglu3, Ahmet Ustundag1, Ugur Kimyon4, Ayse Kalyoncu Ucar1, Ibrahim Adaletli1 and gulen Hatemi3, 1Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Radiology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, New York, NY, 3Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 4Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Istanbul, Turkey

    Background/Purpose: Superb microvascular imaging (SMI) is a novel technique that provides a more sensitive assessment of small vessels compared to color Doppler US (CDUS), by…
  • Abstract Number: 2231 • ACR Convergence 2022

    Earlier and More Aggressive Treatment of Major Organ Involvement with Biologics May Prevent Relapses or Further New Organ Involvement in Behçet’s Disease

    Tugce Bozkurt1, Murat Karabacak1, Hakan Karatas1, seda kutluğ ağaçkıran2, Tulin Ergun3, Haner Direskeneli4 and Fatma Alibaz-Oner5, 1Marmara University, Istanbul, Turkey, 2Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, 3Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey, 4Marmara University, Rheumatology, Istanbul, Istanbul, Turkey, 5Marmara University, Rheumatology, Istanbul, Turkey

    Background/Purpose: Behçet's disease (BD) is a chronic inflammatory disease affecting the eye, nervous system (CNS), vascular and gastrointestinal systems (GIS) as well as skin, mucosa,…
  • Abstract Number: 1046 • ACR Convergence 2021

    Risk of Ocular Comorbidities and Blindness Among Patients with Behçet’s Disease: A Nationwide Population-based Cohort Study in Korea

    SE RIM CHOI1, Anna Shin2, Joo Young Shin3, Hokyung Choung3, You-Jung Ha2, Yun Jong Lee4, Eun bong Lee1, Jin Kyun Park1 and Eun Ha Kang2, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, 3Department of Ophthalmology, Seoul National University College of Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, 4Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea

    Background/Purpose: To examine the risk of ocular comorbidities in a nation-wide cohort of patients with Behçet’s disease (BD) compared to general population in Korea.Methods: We…
  • Abstract Number: 1050 • ACR Convergence 2021

    Epidemiology and Clinical Features of Ophthalmological Manifestations in Behçet’s Disease: Study of 50 Patients of a Series of 120 Patients in a Region in Northern Spain

    Alba Herrero-Morant1, Guillermo Suárez-Amorín1, Rosalia Demetrio-Pablo1, Lara Sánchez-Bilbao1, Carmen Álvarez-Reguera1, David Martinez-Lopez1, Raul Fernandez1, José Luis Martin-Varillas2, Cristina Mata-Arnaiz3, Miguel Ángel gonzalez-Gay4 and Ricardo Blanco5, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Sierrallana, Torrelavega, Spain, 3Hospital Laredo, Santander, Spain, 4Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Ophthalmological involvement is one of the most feared manifestations of Behçet’s disease.The aim of this study was to define the main demographic and clinical…
  • Abstract Number: 1109 • ACR Convergence 2021

    Comparison of Diagnostic Criteria in Behçet’s Disease and Sensitivity in Diagnosing Severe Manifestations

    Carmen Álvarez-Reguera1, Alba Herrero-Morant1, Lara Sánchez-Bilbao1, David Martinez-Lopez1, José Luis Martin-Varillas2, Guillermo Suárez-Amorin1, Maria Cristina Mata-Arnaiz3, Miguel Ángel gonzalez-Gay4 and Ricardo Blanco5, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Sierrallana, Torrelavega, Spain, 3Hospital de Laredo, Spain, Spain, 4Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Behçet disease (BD) is characterized by painful recurrent oral aphthosis genital ulcers and skin lesions. Nevertheless, the major causes of morbidity result from ocular,…
  • Abstract Number: 1727 • ACR Convergence 2021

    Behcet’s Disease: A Meta-analysis of Pregnancy Outcomes

    Leah Rooney1, Aine Gorman2, Matthew Turk3, Louise Moore4, Celine O'Brien5, Jared Bierbrier6, Anne Clohessy5, Eamonn Molloy7, Lorraine O Neill8, Fionnuala M. Mc Auliffe5 and Douglas Veale9, 1St Vincent's University Hospital, Dublin, Ireland, 2St Vincents Hospital, Dublin, Ireland, 3St. Vincents University Hospital, Dublin, Ireland, 4Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Kinnegad, Ireland, 5Perinatal Research Centre, Obstetrics and Gynaecology, School of Medicine, University College Dublin and National Maternity Hospital, Dublin, Dublin, Ireland, 6McMaster University, Hamilton, ON, Canada, 7St Vincent's Healthcare Group, Dublin, Ireland, 8St. Vincent's Hospital, Dublin, Ireland, 9University College Dublin, Dublin, Ireland

    Background/Purpose: Behcet’s disease is a systemic inflammatory disease which commonly presents with episodes of acute inflammation, oral and genital ulcers, uveitis and skin lesions. It…
  • Abstract Number: 1863 • ACR Convergence 2021

    Consistent Efficacy with Apremilast in Men and Women to Treat Oral Ulcers Associated with Behçet’s Syndrome: Results from Phase 3 Researching Oral Apremilast Safety and Efficacy in Behçet’s Disease (RELIEF) Study

    Gülen Hatemi1, Alfred Mahr2, Mitsuhiro Takeno3, Doyoung Kim4, Melike Melikoğlu5, Sue Cheng6, Sven Richter6, Shauna Jardon7, Maria Paris6, Mindy Chen6 and Yusuf Yazici8, 1Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, İstanbul, Turkey, 2Kantonsspital St. Gallen, St.Gallen, Switzerland, 3Musashi Kosugi Hospital, Kawasaki, Japan, 4Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, 5Istanbul University‒Cerrahpaşa, İstanbul, Turkey, 6Amgen Inc., Thousand Oaks, CA, 7Amgen Inc., Gilbert, AZ, 8New York University School of Medicine, New York, NY

    Background/Purpose: Painful, recurring oral ulcers (OU) associated with Behçet’s syndrome negatively affect quality of life (QoL). Differences across sexes were reported in the frequency of…
  • Abstract Number: 1870 • ACR Convergence 2021

    Comparative Study on Anti-TNF vs Tocilizumab for Treatment of Refractory Uveitic Cystoid Macular Edema Due to Behcet’s Disease: Multicenter Study of 49 Patients

    Belén Atienza-Mateo1, Iván Ferraz-Amaro2, Emma Beltrán Catalán3, Alfredo Adán4, Marisa Hernandez Garfella5, Lucía Martínez-Costa6, Miguel Cordero Coma7, Manuel Diaz-Llopis8, José M. Herreras9, Ana Blanco10, Ignacio Torre11, David Díaz-Valle12, Antonio Atanes-Sandoval13, Felix Hernandez14, Santos Insua15, Julio Sánchez16, raquel almodovar17, Oscar Ruiz-Moreno18, Myriam Gandia Martinez19, Joan M. Nolla20, José Luis Martin-Varillas21, Vanesa Calvo-Río22, Diana Prieto-Peña23, Miguel Ángel gonzalez-Gay24 and Ricardo Blanco22, 1Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 3Hospital del Mar, Barcelona, Spain, 4Hospital Clinic, Barcelona, Spain, 5Hospital General Universitario de Valencia, Valencia, Spain, 6Hospital Peset, Valencia, Valencia, Spain, 7Hospital de León, Leon, Spain, 8Hospital Universitario La Fe, Valencia, Spain, 9Hospital Universitario IOBA, Valladolid, Spain, 10Hospital Universitario de Donostia, San Sebastián, 11Hospital Universitario de Basurto, Bilbao, Spain, 12Hospital Clínico San Carlos, Madrid, Madrid, Spain, 13Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, 14Hospital Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain, 15Hospital Universitario Santiago de Compostela, A Coruña, Spain, 16Hospital Universitario 12 de Octubre, Madrid, Spain, 17Hospital Universitario Fundación de Alcorcón, Madrid, Spain, 18Hospital Universitario Miguel Servet, Zaragoza, Zaragoza, Spain, 19Hospital Puerta del Mar, Cádiz, Spain, 20Hospital Universitario de Bellvitge, Barcelona, Barcelona, Spain, 21Hospital Sierrallana, Torrelavega, Spain, 22Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 23Hospital Universitario Marqués de Valdecilla, santander, Spain, 24Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Posterior segment involvement is the most serious affection of uveitis in Behçet’s disease (BD), with cystoid macular edema (CME) being the leading cause of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology